Enclomiphene Citrate Cost vs. Alternatives in Class

How Enclomiphene Citrate Works

Enclomiphene is the trans-isomer of clomiphene citrate, isolated from the racemic mixture that also contains zuclomiphene (the cis-isomer). It functions as a selective estrogen receptor modulator by competitively binding estrogen receptors in the hypothalamus and anterior pituitary gland [1].

This receptor blockade removes estrogen-mediated negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. With that brake released, the hypothalamus increases gonadotropin-releasing hormone (GnRH) pulse frequency. The pituitary responds by secreting more luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [2]. LH drives Leydig cells in the testes to produce testosterone. FSH supports Sertoli cell function and spermatogenesis.

The distinction from exogenous testosterone matters here. Injected or topical testosterone suppresses GnRH, LH, and FSH through negative feedback, which shuts down intratesticular testosterone production and can cause azoospermia within months [3]. Enclomiphene does the opposite. It stimulates the axis rather than replacing its output.

In the Kim et al. trial published in BJU International (2016), men with secondary hypogonadism treated with enclomiphene achieved mean serum testosterone levels above 400 ng/dL while maintaining sperm concentrations, a result that exogenous testosterone cannot replicate [4].

Why Enclomiphene Instead of Regular Clomiphene

Clomiphene citrate (brand name Clomid) contains both enclomiphene and zuclomiphene in a roughly 62:38 ratio. Zuclomiphene has a substantially longer half-life (approximately 30 days vs. 10 hours for enclomiphene) and accumulates with daily dosing [5]. This matters because zuclomiphene carries estrogenic agonist activity, particularly at the level of the liver and bone, and has been linked to the visual disturbances and mood side effects that some men report on clomiphene [6].

By isolating the trans-isomer, enclomiphene delivers the anti-estrogenic hypothalamic blockade without the estrogenic baggage of zuclomiphene. A phase II trial by Wiehle et al. showed that enclomiphene 25 mg daily raised total testosterone from a baseline mean of 228 ng/dL to 454 ng/dL at 3 months, while estradiol levels did not increase disproportionately [7]. That estradiol finding is notable. Men on racemic clomiphene sometimes see estradiol climb high enough to require an aromatase inhibitor add-on, an additional cost and drug interaction to manage.

The clinical question for most patients, though, is whether the cleaner pharmacology justifies the price difference. Generic clomiphene costs $10 to $30 per month at most retail pharmacies. It is FDA-approved (for female ovulatory dysfunction, used off-label in men) and covered by many insurance plans. Compounded enclomiphene runs $30 to $120 per month, has no FDA approval, and is almost never covered by insurance.

Cost Breakdown: Enclomiphene vs. Every Alternative

The monthly out-of-pocket cost for secondary hypogonadism treatment varies by three to tenfold depending on the agent. Here is what each option runs in 2025 to 2026 pricing, based on GoodRx estimates and compounding pharmacy surveys.

Clomiphene citrate (generic Clomid). $10 to $30 per month for 25 to 50 mg daily. The cheapest SERM option. Widely available at retail pharmacies. Off-label for men, but prescribers are familiar with it and prior authorization is rarely required [8].

Enclomiphene citrate (compounded). $30 to $120 per month for 12.5 to 25 mg daily. Only available through compounding pharmacies, as the FDA has not approved a commercial product. Repros Therapeutics (later Allergan) pursued approval under the brand name Androxal but received a Complete Response Letter from the FDA in 2015 citing assay concerns [9]. The drug remains in regulatory limbo.

Tamoxifen (generic Nolvadex). $15 to $40 per month for 10 to 20 mg daily. Another SERM with data supporting testosterone elevation in hypogonadal men. A study by Tsourdi et al. reported that tamoxifen 20 mg daily raised testosterone by an average of 161% in men with idiopathic oligozoospermia [10]. Tamoxifen carries a small but real risk of thromboembolic events.

Anastrozole (generic Arimidex). $10 to $35 per month for 1 mg daily or every other day. An aromatase inhibitor, not a SERM. It raises testosterone by preventing the conversion of testosterone to estradiol, which reduces estrogen-mediated negative feedback. The Endocrine Society's 2018 guidelines recommend against aromatase inhibitors as monotherapy for male hypogonadism due to concerns about bone mineral density loss with long-term estradiol suppression [11].

Human chorionic gonadotropin (hCG). $150 to $300+ per month for 1,500 to 3 to 000 IU two to three times weekly. hCG mimics LH at the Leydig cell receptor, stimulating intratesticular testosterone production. It preserves spermatogenesis. The cost is substantially higher, and subcutaneous injections are required. Following FDA enforcement actions against compounding pharmacies in 2020, only brand-name Pregnyl and biosimilar products remain widely available, increasing the price floor [12].

Testosterone cypionate (injectable TRT). $30 to $80 per month for 100 to 200 mg weekly intramuscularly or subcutaneously. This is the cheapest option per milligram of testosterone delivered, but it suppresses the HPG axis, eliminates spermatogenesis in most men within 3 to 6 months, and requires ongoing monitoring of hematocrit, PSA, and lipids [3]. Dr. Abraham Morgentaler of Harvard Medical School and Men's Health Boston has stated: "Exogenous testosterone is effective at raising T levels but is contraindicated in any man who wants to preserve fertility in the near term" [13].

Testosterone gel (AndroGel, Testim, generic). $50 to $400+ per month depending on brand vs. generic and insurance coverage. Same HPG axis suppression as injectable testosterone. Higher cost, with the added risk of transdermal transfer to partners or children.

Efficacy Comparison: What the Data Actually Show

Head-to-head trials between these agents are limited, but the available evidence allows reasonable comparisons across several endpoints.

Testosterone elevation. In the Wiehle et al. phase II data, enclomiphene 25 mg raised mean total testosterone from 228 ng/dL to 454 ng/dL (a 99% increase) over 3 months [7]. Clomiphene 50 mg daily has shown comparable testosterone increases. A retrospective analysis by Ramasamy et al. (2014) found that clomiphene raised mean testosterone from 228 ng/dL to 612 ng/dL in 86 men over a median follow-up of 19 months [14]. These numbers suggest that racemic clomiphene may produce a numerically higher testosterone response, possibly because zuclomiphene contributes some additional hypothalamic blockade at steady state, though this has not been confirmed in a controlled comparison.

Sperm parameters. Both enclomiphene and clomiphene preserve spermatogenesis. Kim et al. demonstrated no decline in sperm concentration or motility with enclomiphene treatment over 6 months [4]. hCG also maintains sperm production. Testosterone replacement, by contrast, can reduce sperm counts to <1 million/mL in over 65% of men within 6 months according to data from the male hormonal contraception trials [15].

Side effects. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that SERMs can cause hot flashes, visual changes, and mood disturbances [11]. Enclomiphene appears to produce fewer visual side effects than racemic clomiphene based on Phase III safety data reported by Repros Therapeutics, though these data were presented at conferences and not published in peer-reviewed form after the FDA's rejection. Dr. Mohit Khera of Baylor College of Medicine has noted: "Enclomiphene's theoretical advantage is the removal of zuclomiphene, which we believe is responsible for the visual symptoms some men experience on Clomid" [16].

Anastrozole carries a unique risk profile. While it raises testosterone, chronic estradiol suppression below 20 pg/mL has been associated with decreased bone mineral density and adverse lipid changes [11]. The Endocrine Society explicitly recommends against AI monotherapy for hypogonadism for this reason.

Who Should Consider Enclomiphene Over Cheaper Options

The strongest case for enclomiphene over generic clomiphene applies to men who experience side effects on racemic clomiphene, specifically visual disturbances, mood instability, or elevated estradiol requiring AI co-administration. If a patient tolerates clomiphene well and achieves target testosterone levels, switching to enclomiphene at three to five times the cost offers limited clinical advantage.

Men prioritizing fertility preservation should consider either a SERM (enclomiphene or clomiphene) or hCG. The choice between these two classes often comes down to cost tolerance and route of administration. SERMs are oral and cheaper. hCG requires injections but directly stimulates testicular testosterone production without relying on intact pituitary function, making it the better option for men with pituitary pathology.

For men with no fertility concerns, injectable testosterone cypionate remains the most cost-effective treatment per unit of testosterone delivered, at $30 to $80 per month with predictable dose-response pharmacokinetics [3]. The trade-off is HPG axis suppression, testicular atrophy, and the need for lifelong treatment or a difficult recovery period if discontinuing.

Insurance, Compounding, and Access Realities

Enclomiphene's lack of FDA approval creates a practical access barrier that goes beyond price. Most commercial insurers and Medicare Part D plans do not cover compounded medications. Patients pay cash. Compounding pharmacy quality varies, and the FDA has issued warning letters to several compounders for potency deviations in hormonal products [17].

Generic clomiphene and generic anastrozole are Tier 1 generics on most formularies, often costing $4 to $15 with insurance. Tamoxifen is similarly inexpensive. Brand-name hCG products like Pregnyl are covered by some plans under specialty pharmacy benefits, but the copay can still reach $75 to $150 per month.

For men without insurance or with high-deductible plans, the cost ranking from cheapest to most expensive is: clomiphene or anastrozole ($10 to $35) > enclomiphene compounded ($30 to $120) > testosterone cypionate generic ($30 to $80) > hCG brand ($150 to $300+) > testosterone gel brand ($200 to $400+).

Patients considering compounded enclomiphene should verify that their pharmacy holds current state licensure, uses third-party potency testing, and follows USP <795> or <797> standards for non-sterile or sterile compounding, respectively [17].

The Regulatory Outlook for Enclomiphene

Repros Therapeutics submitted two New Drug Applications for enclomiphene (under the brand name Androxal) targeting secondary hypogonadism. The FDA issued Complete Response Letters in both 2009 and 2015 [9]. The 2015 rejection cited concerns about the testosterone assay methodology used in the key trials, not efficacy or safety failures. Repros was subsequently acquired by Allergan, which did not pursue resubmission.

No company currently holds an active IND or NDA for enclomiphene in the United States. This means the drug exists in a gray zone: widely prescribed through compounding pharmacies, supported by published clinical data, but lacking the FDA stamp that would trigger insurance coverage and standardize manufacturing quality.

If a commercial product were approved, pricing would likely fall between generic clomiphene and brand-name hCG, based on the market positioning of other specialty reproductive endocrinology drugs. Until that happens, patients remain dependent on compounding pharmacies and cash pricing.